AADI - צמיחת הכנסות ב-12 חודשים נגררים Aadi Bioscience, Inc.

Aadi Bioscience price action is based on the uniqueness of Fyarro therapy for rare PEComa tumors. The historical year-over-year revenue growth trend over the last 12 months visualizes this process, where 112.00 represents the current level of the metric. Scientific authority in targeted oncology strengthens the brand's position, although high dependence on a single drug and R&D expenses create certain risks.
Aadi Bioscience - פילוחים אנליטיים ומדדי מפתח (AADI)

For Aadi Bioscience (AADI), the TTM annual sales growth on the GURU.Markets platform reflects the commercial success of Fyarro within the rare sarcoma segment. This indicator calculates the percentage change in revenue over a rolling year with daily updates, allowing investors to differentiate real market demand from temporary spikes and assess the risk of a future capital value correction should expansion rates slow.